Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

T cell immunity enhanced by timing of interleukin-7 therapy

05.02.2008
That the cell nurturing growth factor interleukin-7 can help ramp up the ability of the immune system to remember the pathogenic villains it encounters is well known.

But precisely how this natural protein works its magic on the cells of the immune system is not well understood. Now, however, in research that may have implications for developing vaccines against HIV and cancer, a team of scientists from the University of Wisconsin-Madison has found that the timing of interleuin-7 therapy is critical for increasing the number of killer cells that zero in on and destroy virus-infected cells.

Writing in the current online issue (Feb. 1, 2008) of the Journal of Clinical Investigation, a team led by UW-Madison School of Veterinary Medicine Professor of pathobiological sciences Marulasiddappa Suresh reports that therapeutic administration of interleukin-7 can be linked to a stage of early infection to effectively increase the number of a type of killer cell that recognizes and selectively assassinates virus-infected cells.

"These cells need to get interleukin-7 for their survival," explains Suresh, of the killer immune cell known as CD8 T cells, a type of white blood cell that attacks virus-infected cells, foreign cells and cancer cells. Interleukin-7 is produced in very small amounts in bone marrow, spleen, and the thymus, but scientists have been able to isolate and synthesize the agent, which is now in pre-clinical testing for a variety of conditions.

"This is one of the most exciting cytokines in pre-clinical human trials," says Suresh. "The idea is that it might be used as an immune restorative agent. It is absolutely essential for normal development and functioning of the immune system."

Effectively stimulating the immune system -- the complex of organs and cells that defends the body against infection and disease -- is a grail of biomedical science in the fight against infectious diseases.

Suresh explains that upon infection, the body unleashes an army of T cells to fight infected or rogue cells. But when the body perceives an infection may be contained, the number of T cells it deploys is dramatically reduced. However, a certain number of T cells, known as memory cells and that are capable of recognizing a recently vanquished foe, remain. Stimulating memory T and B cells is the basis of vaccination, but vaccines often do not induce a sufficient number of memory CD8 T cells.

Interleukin-7 is a well-studied growth factor that is known to help generate and maintain the immune system's “memory” CD8 T cells, which have the ability to remember the identity of its targets, such as cancer cells or cells that have been taken over by a virus. A paucity of interleukin-7 is believed to limit the survival and persistence of memoryCD8 T cells.

Despite the promise of interleukin-7 as a means to bolster immunity, an optimal treatment regimen has yet to be determined.

In studies in mice, Suresh and his colleagues found that T cell memory is best enhanced when interleukin-7 is administered during a phase of infection when the number of T cells is ramping down.

In the new Wisconsin study, Suresh's group gave interleukin-7 to mice during different stages of a viral infection. They found that by administering interleukin-7 when the number of T cells is in decline, it is possible to increase the number of memory CD8 T cells that remain to stand guard and protect against re-infection.

"The purpose of the immune response is to expand these cells," says Suresh, explaining that T cells act like serial killers, snuffing one infected cell after another until the viral infection is controlled.

During the expansion phase of infection, when the body is generating the most T cells, administration of interleukin-7 seems to have no effect, according to Suresh. But during the contraction phase, memory is increased.

"We tried this in a DNA vaccine and it works," says Suresh. "Even with the weakest vaccine, we could increase the memory cells and improve protection against infection. What this shows is that the number of memory cells are not predetermined. You can increase them and interleukin-7 drives their proliferation."

Marulasiddappa Suresh | EurekAlert!
Further information:
http://www.vetmed.wisc.edu

Further reports about: CD8 Infection Suresh T cells Vaccine immune system interleukin-7

More articles from Life Sciences:

nachricht Multi-institutional collaboration uncovers how molecular machines assemble
02.12.2016 | Salk Institute

nachricht Fertilized egg cells trigger and monitor loss of sperm’s epigenetic memory
02.12.2016 | IMBA - Institut für Molekulare Biotechnologie der Österreichischen Akademie der Wissenschaften GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>